EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC0

Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis

Tasnim F Imran iD, Ali A Khan iD, Phinnara Has, Alexis Jacobson, Stephanie Bogin, Mahnoor Khalid, Asim Khan, Samuel Kim, Sebhat Erqou, Gaurav Choudhary, Karen Aspry, Wen-Chih Wu iD

PLOS ONE · 06.12.2023 · 18 (12) · e0295359

DOI: 10.1371/journal.pone.0295359 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift PLOS ONE, online erschienen am 06.12.2023. Verfasst von Tasnim F Imran und 11 weiteren Autor:innen. Beteiligte Einrichtung: Providence VA Medical Center, Providence, Rhode Island, United States of America. Hauptthemen laut MEDLINE: Myocardial Infarction, Atherosclerosis, Anticholesteremic Agents, Cardiovascular Diseases. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: NIGMS NIH HHS, NIGMS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system. Thus, lipid lowering therapy is essential for both primary and secondary prevention. Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors (Evolocumab, Alirocumab) and small interfering RNA (siRNA) therapy (Inclisiran) have been demonstrated to lower LDL-c and ASCVD events in conjunction with maximally tolerated statin therapy. However, the degree of LDL-c reduction and the impact on reducing major adverse cardiac events, including their impact on mortality, remains unclear.

Objective

The purpose of this study is to examine the effects of PCSK9 inhibitors and small interfering RNA (siRNA) therapy on LDL-c reduction and major adverse cardiac events (MACE) and mortality by conducting a meta-analysis of randomized controlled trials.

Methods

Using Pubmed, Embase, Cochrane Library and clinicaltrials.gov until April 2023, we extracted randomized controlled trials (RCTs) of PCSK9 inhibitors (Evolocumab, Alirocumab) and siRNA therapy (Inclisiran) for lipid lowering and risk of MACE. Using random-effects models, we pooled the relative risks and 95% CIs and weighted least-squares mean difference in LDL-c levels. We estimated odds ratios with 95% CIs among MACE subtypes and all-cause mortality. Fixed-effect model was used, and heterogeneity was assessed using the I 2 statistic.

Results

In all, 54 studies with 87,669 participants (142,262 person-years) met criteria for inclusion. LDL-c percent change was reported in 47 studies (n = 62,634) evaluating two PCSK9 inhibitors and siRNA therapy. Of those, 21 studies (n = 41,361) included treatment with Evolocumab (140mg), 22 (n = 11,751) included Alirocumab (75mg), and 4 studies (n = 9,522) included Inclisiran (284mg and 300mg). Compared with placebo, after a median of 24 weeks (IQR 12–52), Evolocumab reduced LDL-c by -61.09% (95% CI: -64.81, -57.38, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myocardial InfarctionAtherosclerosisAnticholesteremic AgentsCardiovascular DiseasesHydroxymethylglutaryl-CoA Reductase InhibitorsHumansPCSK9 InhibitorsCholesterol, LDLProprotein Convertase 9Heart Disease Risk FactorsRNA, Small Interfering

Substanzen

PCSK9 InhibitorsCholesterol, LDLProprotein Convertase 9RNA, Small InterferingAnticholesteremic AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsPCSK9 protein, human

Autor:innen und Institutionen

  • Providence VA Medical Center, Providence, Rhode Island, United States of America.
  • Lifespan Cardiovascular Institute, Rhode Island and Miriam Hospitals, Providence, Rhode Island, United States of America.
  • Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States of America.
  • Northwestern University, Evanston, Illinois, United States of America.
  • Weil Cornell College of Medicine, New York, New York, United States of America.

ORCID-Profile: Tasnim F Imran, Ali A Khan, Wen-Chih Wu

Förderung

  • NIGMS NIH HHS
  • NIGMS

Zitieren

APA

Imran, T. F., Khan, A. A., Has, P., Jacobson, A., Bogin, S., Khalid, M., Khan, A., Kim, S., Erqou, S., Choudhary, G., Aspry, K., & Wu, W. C. (2023). Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis. PLOS ONE, 18(12), e0295359. https://doi.org/10.1371/journal.pone.0295359

Vancouver

Imran TF, Khan AA, Has P, Jacobson A, Bogin S, Khalid M, et al. Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis. PLOS ONE. 2023;18(12):e0295359. doi:10.1371/journal.pone.0295359

BibTeX
@article{Imran2023,
  author = {Imran, Tasnim F and Khan, Ali A and Has, Phinnara and Jacobson, Alexis and Bogin, Stephanie and Khalid, Mahnoor and Khan, Asim and Kim, Samuel and Erqou, Sebhat and Choudhary, Gaurav and Aspry, Karen and Wu, Wen-Chih},
  title = {Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis},
  journal = {PLOS ONE},
  year = {2023},
  volume = {18},
  number = {12},
  pages = {e0295359},
  doi = {10.1371/journal.pone.0295359}
}
Kostenlos starten →